New York Medical College incubator adds therapeutics startup

By Ryan Deffenbaugh

No Comment

New York Medical College’s BioInc@NYMC biotech incubator will add a seventh tenant to its Valhalla campus.

Sapience Therapeutics Inc., joined the incubator, the school recently announced. Sapience is developing novel therapeutics to address high-mortality cancers.

The therapeutics startup recently raised $22.5 million in its first round of financing. That money will primarily support the development of Sapience’s main drug candidate, ST-36, which targets a protein that promotes the growth of several types of tumors, including glioblastoma, the most severe and deadly form of brain cancer.

“The BioInc@NYMC incubator provides us with the resources to develop our novel treatment approaches and flexibility to grow as needed,” said Barry Kappel, president and CEO of Sapience Therapeutics.  “Importantly, BioInc@NYMC allows a startup such as Sapience to hit the ground running and work towards our goal of saving patients’ lives.”

Launched in October 2014, BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building at 7 Dana Road in Valhalla. The incubator operates as a public-private enterprise, combining resources from the federal government, the state, Westchester County and NYMC.  It has also been approved by Start-Up NY space and received the Mid-Hudson Innovation Hot Spot award granted by the New York State Regional Economic Development Council.


About the author

Ryan Deffenbaugh covers energy, education, food and beverage and the Sound Shore for the Westchester County Business Journal. He previously worked for Westchester Magazine and The Citizen daily newspaper (Auburn, N.Y.). He started with the Westchester County Business Journal in March 2016.

Related Articles